Flow cytometric expression of bcl-2 protein was analyzed in 90 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB cytotype, CD34 expression and clinical outcome. Bcl-2 was expressed in all AML cases with different intensity. The mean fluorescence index (MFI), expressed as the ratio of sample mean channel:control mean channel, ranged from 3.0 to 39.5 with a median value of 14. The MFI was significantly higher (P = 0.01) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4), M4 (11.8) and M5 (9.5) cytotypes. In addition, bcl-2 MFI significantly correlated both with CD34 positivity (P = 0.001) and with CD34 MFI (P = 0.01), being CD34 antigen expressed in 65% of patients with a bcl-2 MFI Ͼ14, and only in 35% of AML cases with a bcl-2 MFI Ͼ14. When bcl-2 intensity expression was correlated with complete remission (CR) rate, a higher MFI was associated with a low CR rate after standard intensive chemotherapy. In particular, CR was achieved in 86% of patients with a bcl-2 MFI Ͻ14, but only in 57% of patients with a MFI Ͼ14 (P = 0.008). A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. By statistical analysis we also demonstrated that both bcl-2 high MFI (Ͼ14) and CD34 expression are independent prognostic factors for achieving CR in AML. These data raise the hypothesis that high values of bcl-2 may confer on myeloid blasts a higher resistance to standard chemotherapy. However, identification of patients with high expression of bcl-2 may be important for a different therapeutic approach.
Introduction
The t(14;18) translocation reflects recombination of the bcl-2 oncogene on chromosome 18 with the immunoglobulin heavy chain locus on chromosome 14 [1] [2] [3] [4] and this results in an increased expression of a 26 kDa mitochondrial protein which prolongs lymphoid cell survival by blocking programmed cell death. [5] [6] [7] Bcl-2 protein was firstly identified in mantle zone B lymphocytes and in follicular lymphomas. 8, 9 Further studies documented its expression in several other lymphoproliferative disorders 10 and also in non-lymphoid tissue, including skin and bone marrow, 11 even in the absence of t(14;18) translocation. [12] [13] [14] Recently, using a specific monoclonal antibody (MoAb), bcl-2 protein has also been detected in patients with untreated acute myeloblastic leukemia (AML) and correlation with an elevated number of blasts, monoblastic subtype and prognostic outcome has been found. 15, 16 On the basis of these observations, we investigated the presence of bcl-2 protein in 90 AML patients at diagnosis, using a direct immunofluorescent method. Results were correlated Correspondence: D Raspadori, Istituto di Ematologia e Oncologia Medica 'Seràgnoli', Via Massarenti, 9, 40138 Bologna, Italy; Fax: 051 398973 Received 9 July 1996; accepted 24 July 1997 with the presence of CD34-positive blast cells and with the probability of achieving complete remission (CR). Therefore, the identification of prognostic factors in AML may help to recognize high-risk patients who will probably need a more intensive therapeutical approach.
Patients and methods
The cytofluorimetric expression of bcl-2 protein was investigated in 90 consecutive untreated AML adult patients classified according to FAB criteria, and studied for cell-surface immunophenotype and cytogenetics. All AML patients except for M3 cases were treated with a standard chemotherapy regimen including daunorubicin (× 3 days) and cytosine arabinoside (× 7 days continuous infusion), while M3 patients also had treatment with all-trans retinoic acid (ATRA).
Isolation of leukemic cells and immunophenotyping
Leukemic cells were obtained following Lymphoprep (Nycomed Pharma, Oslo, Norway) gradient separation from bone marrow and/or peripheral blood of AML patients. In all samples leukemic blasts represented Ͼ90% of cellularity. After washing twice the cells were resuspended in RPMI 1640 medium (Seromed Biochrom, Berlin, Germany) supplemented with heat-inactivated fetal bovine serum (Seromed) and 10% dimethylsulfoxide (DMSO) and frozen in liquid nitrogen. Before evaluation of immunophenotype and bcl-2 expression, the blasts were thawed, washed twice, incubated at 37°C overnight, tested for viability with propidium iodide staining and analysis carried out only if viable cells were Ͼ90%. Immunophenotype was performed using a panel of fluorescein (FITC) and phycoerythrin (PE)-conjugated MoAbs reactive with myeloid and lymphoid antigens (CD13, CD33, CD34, CD2, CD7, CD4, CD10, CD19) (Becton Dickinson, San José, CA, USA) in flow cytofluorimetric analysis (FACScan and FACS Vantage; Becton Dickinson), as previously described. 17 In particular, CD34 positivity was defined as expression of this molecule on Ͼ15% of blasts.
bcl-2 Expression
The bcl-2 expression was analyzed by direct immunofluorescence technique using an anti-bcl-2 124 FITC MoAb (Dako, Glostrup, Denmark). The study was performed either with fresh or cryopreserved cells, since expression of bcl-2 protein was not modified by cryopreservation in DMSO and thawing, as demonstrated by de Jong et al. 18 In all cases 1 × 10 6 cells per sample were fixed for 10 min at 4°C with 1 ml of 2% paraformaldehyde, washed twice, permeabilized using 50 l of 0.02% saponine and incubated with anti-bcl-2 MoAb for 30 min at 4°C. Negative control was performed by incubating the cells with appropriate isotype IgG 1 FITC MoAb (Becton Dickinson). Data acquisition and analysis were performed by Lysys II software (Becton Dickinson). In all cases 10 000 events were acquired and analysis was restricted to leukemic populations by gating on forward and side light scatter parameters. Bcl-2 expression was defined by considering both the percentage of positive cells and the mean fluorescence index (MFI) expressed as the ratio of sample mean channel:control mean channel.
Statistical analysis
In order to establish whether the intensity of expression of bcl-2 protein and/or CD34 expression on blast cells may independently affect the probability of achieving CR, we performed a statistical analysis by the linear logistic model, 19 BMDP Statistical Software, 1991 (BDM Statistical Software, Cork, Ireland). Patients who died prior to day 14 were excluded from analysis for remission, while all patients were included in survival and event-free survival analysis. Difference in response rates among subgroups of patients was analyzed by 2 test.
Results
Bone marrow and/or peripheral blood leukemic samples from 90 patients, morphologically and cytochemically diagnosed as AML were analyzed for the purpose of this study. Fifty-three were males and 37 were female with a median age of 45 years (range 14-82). According to FAB criteria, five patients were M0, 19 M1, 12 M2, 13 M3, 26 M4 and 15 M5. Samples from all patients were studied with a large panel of MoAbs, as previously reported, 17 and since we recently demonstrated that CD34 expression may influence the clinical response in AML patients, 20 we addressed the hypothesis of whether bcl-2 expression might also correlate with FAB cytotype, CD34 expression and clinical outcome.
Correlation of bcl-2 with FAB and CD34 expression Bcl-2 protein was detected in all 90 AML cases with an average of 82% positive cells (range: 28-99%). The MFI ranged from 3.0 to 39.5 with a median value of 14. Thirty-nine out of 90 patients showed an increased intensity of bcl-2 expression with a MFI Ͼ14, while in the remaining 51 cases the bcl-2 expression was lower (MFI Ͻ14). The mean bcl-2 MFI was significantly higher (P = 0.001) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4) cytotypes or in M4 (11.8) and M5 (9.7) cases. Correlation between bcl-2 MFI and FAB subtypes is shown in Table 1 . High bcl-2 MFI did not correlate Table 1 Correlation of bcl-2 fluorescence intensity with FAB cytotypes
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MFI Ͼ14  Total   51  39  90  FAB  M0  2  3  5  M1  5  14  19  M2  7  5  12  M3  9  4  13  M4  16  10  26  M5  12  3  15 with the expression of lineage-specific markers such as CD13, CD33, CD2, CD7, CD4, CD10 and CD19, but significantly correlated both with CD34 positivity (P = 0.01) and with CD34 MFI (P = 0.01) (data not shown). In particular, CD34 antigen was present in 64% of patients with a MFI Ͼ14, and only in 35% of AML cases with a MFI Ͻ14 ( Table 2) . Cytogenetics was performed in the majority of our cases but no correlation between specific abnormalities and bcl-2 intensity of expression was documented. In particular, good-risk abnormalities such as inv (16) and t(15;17) were observed, respectively, in four patients: two with bcl-2 MFI Ͼ14 and two with bcl-2 MFI Ͻ14, and in all M3 cases. On the other hand, single poor risk alterations such as 5q− or t(3;3) or complex karyotypic abnormalities were found only in seven out of 39 patients with bcl-2 MFI Ͼ14. Also, bcl-2 expression was variably detected on leukemic cells of patients who did not achieve a complete response. The example in Figure 1 shows an M4 case, resistant to induction chemotherapy, in which bcl-2 appears highly expressed only on a fraction of blasts before treatment, while it is expressed with high intensity on all residual blasts after treatment.
Correlation of bcl-2 with remission rate and outcome
To address the hypothesis that bcl-2 expression could represent a prognostic factor in AML it was correlated with clinical response. Among patients evaluable for response CR was achieved in 37/43 patients (86%) with bcl-2 MFI Ͻ14, but only in 17/30 cases (57%) with bcl-2 MFI Ͼ14 (P = 0.008) ( Table 2) . A further decrease of CR rate to 41% was observed in patients who, in addition to a higher bcl-2 MFI, also showed the presence of CD34 antigen on their blasts. Nevertheless, at the moment the mean duration of remission in patients with bcl-2 MFI Ͻ14 (11.6 months) and Ͼ14 (9.3 months) is not statistically different. Also, no significant differences are observed in the overall and event-free survival curves of the two groups of patients (data not shown), probably because a large number of patients have undergone autologous or allogeneic matched related bone marrow transplant. Furthermore, in order to evaluate if any among age, bcl-2 MFI and CD34 expression could influence the outcome of events, adjustment for covariate was performed by the linear logistic regression model. Age did not influence the outcome of patients with high or low expression of bcl-2 and CD34, whereas bcl-2 MFI and CD34 represented independent prognostic factors for the achievement of CR in AML (Table 3) . Also, higher CD34 MFI was observed to correlate with lower probability of obtaining a CR (data not shown). These results suggest that both bcl-2 and CD34 are associated with remission even when considered as continuous variables. 
Figure 1
Expression of bcl-2 protein at diagnosis and after induction therapy in a 'resistant' M4 AML case. Flow cytometric forward light scatter (FSC) vs side light scatter (SSC) dot plot at diagnosis (a). Two blast cell populations (R1 and R2) were identified. Bcl-2 protein was expressed in cells gated in R1 (b), but not in R2 (c). Following induction therapy, only one blast cell population was left (d), and bcl-2 was brightly expressed in all the cells (e). In both analyses 10 000 cells were processed.
Table 3
Statistical significance of CD34 expression and bcl-2 MFI as prognostic factors in the achievement of CR in 90 AML patients To determine whether CD34 and bcl-2 MFI could influence the outcome of AML patients, adjustment for covariates was performed by the linear logistic regression model. ␤-Coefficients were calculated for each variable according to the model. Since the logistic coefficient for CD34 and bcl-2 MFI were negative, the probability of achieving a CR was smaller for patients with higher positivity.
Discussion
This study demonstrates that bcl-2 protein is variably expressed on the blasts of all AML patients, particularly in those with M0, M1 cytotypes. Moreover, we indicate that a high bcl-2 expression on AML blasts correlates with CD34 positivity and is an independent poor prognostic factor in the probability of achieving CR after standard chemotherapy. It is well known that bcl-2 is a novel type of oncogene and its product is an inner mitochondrial membrane protein that plays a role in blocking the programmed cell death of B lymphocytes within follicular centers. 11 Initially found in follicular lymphoma, bcl-2 protein has been recently detected by flow cytometry in several myeloblastic cell lines 21 and also on leukemic blasts in a proportion of patients with AML, particularly in those with M1 and monoblastic subtypes (M4, M5). 15 In this latter study, although the number of bcl-2-positive cells in each sample was extremely variable (0-35%, with a mean of 23%) it demonstrated a strict correlation between the number of bcl-2-positive cells and both duration of blast survival in liquid culture and the poor prognostic outcome of patients. In our study, probably due to a more sensitive technical approach by direct immunofluorescence, all AML cases were found bcl-2 positive. Furthermore, according to the bcl-2 MFI median value calculated in our study, we divided the patients into two groups with low and high intensity of bcl-2 expression. AML patients showing M4 and M5 cytotype had a significantly (P = 0.01) lower bcl-2 expression with respect to M0 and M1 cytotypes. Since expression of lymphoid-associated antigens does not influence the outcome of adult AML patients, 17 no conclusions can be drawn by any relationship between their presence and bcl-2 expression. Moreover, we found a significant correlation between higher bcl-2 expression (MFI Ͼ14) and coexpression of CD34 antigen, further suggesting that the higher bcl-2 expression was more evident in less differentiated AML cases. Our results on M4 and M5 cytotypes differ from those of Campos et al 15 probably because those authors based their results on different proportions of bcl-2-positive cells in each FAB subtype, while our findings indicate that all AML samples do have bcl-2-positive cells, although with different values of MFI. Moreover, the quantification of fluorescence intensity seems technically adequate and useful for a more correct evaluation of clinical and prognostic correlations, as previously demonstrated for the expression of CD34 in AML patients. 20 In fact, we found that CR rates obtained after standard chemotherapy for AML could be highly predicted by bcl-2 intensity of expression. In particular, 86% of patients showing a lower bcl-2 MFI experienced a CR while only 57% of those showing a higher bcl-2 MFI achieved CR. Moreover, the CR rate further decreased to 41% in patients whose blasts also coexpressed the CD34 antigen. Finally, by statistical analysis according to Cox's linear logistic regression model we demonstrated that not only CD34 expression but also CD34 MFI and bcl-2 MFI are independent prognostic factors, since the probability of response was smaller for AML patients with higher bcl-2 and CD34 positivity. Therefore, bcl-2 and CD34 are associated with the clinical outcome of AML patients when also considered as continuous variables. On the basis of these results, it could be hypothesized that high bcl-2 expression may confer to the myeloid blasts a higher resistance to standard chemotherapy, which has been emphasized particularly in patients with CD34-positive blasts, probably by reducing programmed cell death and through additional mechanisms such as increased multi-drug resistance. 22 In conclusion, these findings suggest that high bcl-2 expression, as well as CD34 expression, represent a predictive adverse prognostic factor in AML patients. Therefore, the identification of patients with these phenotypical characteristics may be important in strategically designing a more aggressive therapeutic approach.
